Mifepristone Achieves Significant Glycemic Improvement in Diabetes Patients with Hypercortisolism

Are We Witnessing a Breakthrough in Glycemic Control?

Mifepristone Shows Significant Glycemic Benefits in Type 2 Diabetes Patients with Hypercortisolism, CATALYST Trial Reports

The CATALYST clinical trial has demonstrated that mifepristone (Korlym) significantly improved glycemic control in patients with inadequately controlled type 2 diabetes (T2D) who were found to have endogenous hypercortisolism. The randomized, double-blind, placebo-controlled study showed a substantial 1.32% placebo-adjusted reduction in HbA1c after 24 weeks of treatment, potentially offering a new approach for patients who remain above target despite multiple glucose-lowering medications.

What Is the Background Behind This Novel Approach?

The trial, which enrolled 136 participants in a 2:1 ratio (91 receiving mifepristone and 45 receiving placebo), builds on findings from the prevalence phase of CATALYST, which identified hypercortisolism in nearly one-quarter (23.8%) of patients with inadequately controlled T2D using the 1-mg overnight dexamethasone suppression test (DST). This prevalence aligns with findings from several smaller studies suggesting that unrecognized hypercortisolism might play a significant role in treatment resistance among certain diabetes patients. The study participants had a mean baseline HbA1c of 8.55% despite receiving multiple glucose-lowering medications, including insulin in most cases.

Hypercortisolism can negatively impact glucose control through various mechanisms, including increased insulin resistance, impaired β-cell function, inhibition of incretin effects, increased lipolysis, and enhanced hepatic glucose production. While Korlym (mifepristone) is already approved for treating hyperglycemia secondary to endogenous hypercortisolism in adult patients with T2D or glucose intolerance, the CATALYST trial is the first randomized, placebo-controlled study to demonstrate efficacy specifically in patients with non-neoplastic hypercortisolism identified through DST screening.

Do the Clinical Results Outweigh the Risks?

The primary endpoint results were compelling, with mifepristone demonstrating a mean HbA1c reduction from 8.62% at baseline to 7.12% at week 24 (LSM change -1.47%), compared with minimal change in the placebo group (8.41% to 8.36%; LSM change -0.15%). Importantly, these glycemic improvements were accompanied by reductions in glucose-lowering medications, particularly insulin. Within the first 12 weeks of treatment, dose reductions or discontinuations of fast-acting insulin occurred in 30% of mifepristone-treated patients versus 11% on placebo, while long-acting insulin reductions were seen in 49% versus 13%, respectively. Secondary endpoints also showed significant benefits, including a placebo-adjusted weight loss of 5.12 kg, BMI reduction of 1.75 kg/m², and waist circumference decrease of 5.1 cm at 24 weeks, suggesting meaningful improvements in metabolic parameters beyond glycemic control.

However, treatment with mifepristone was associated with notable adverse events, resulting in a higher discontinuation rate compared to placebo. Hypokalemia occurred in 29.7% of mifepristone-treated patients compared to none in the placebo group, and was among the most common reasons for treatment discontinuation. Other common adverse events included fatigue, nausea, vomiting, peripheral edema, and increases in systolic blood pressure. While these adverse events were mostly mild to moderate in severity, they highlight the need for careful monitoring and management in clinical practice. The study authors noted that the double-blind nature of the trial may have contributed to the discontinuation rate, as proactive management strategies like spironolactone administration and insulin dose adjustments could not be systematically implemented.

The findings from CATALYST have significant implications for clinical practice, suggesting that screening for hypercortisolism using the DST should be considered in patients with T2D who appear resistant to conventional glucose-lowering therapies. "Our data suggest that a DST, performed in an appropriately selected patient population with exclusion of common causes for false-positive results, identifies individuals who may benefit from cortisol-directed pharmacotherapy," the study authors noted. This approach could potentially identify a subpopulation of diabetes patients who might benefit more from cortisol-directed therapy than from additional glucose-lowering medications.

How Will This Shape the Future of Diabetes Management?

For pharmaceutical companies, the results open new possibilities in the diabetes treatment landscape, which has been dominated by therapies targeting insulin resistance, secretion, or renal glucose handling. Corcept Therapeutics, the manufacturer of Korlym, may find opportunities to expand the drug's indications or develop next-generation selective glucocorticoid receptor antagonists with improved safety profiles. The study also creates potential opportunities for diagnostic companies to develop improved screening tools for hypercortisolism in diabetes populations.

Looking ahead, the authors emphasized the need for longer-term studies to demonstrate the benefits of treating hypercortisolism for other clinical outcomes beyond glycemic control. Future research will likely focus on refining patient selection criteria, optimizing treatment protocols to minimize adverse events, and evaluating the cost-effectiveness of routine screening for hypercortisolism in appropriate T2D populations. The potential to identify a distinct pathophysiological subtype of diabetes that responds differently to treatment represents an important step toward more personalized approaches to diabetes management.

Industry Context: The CATALYST trial findings come at a time when the diabetes treatment landscape is increasingly focused on precision medicine approaches and addressing underlying pathophysiological mechanisms rather than simply treating hyperglycemia. While GLP-1 receptor agonists and SGLT-2 inhibitors have dominated recent innovation in diabetes care, the identification of hypercortisolism as a potentially treatable factor in a substantial subset of patients highlights the continued importance of endocrine evaluation in cases of treatment resistance. This approach contrasts with the current trend toward escalating doses of newer agents and may prompt reassessment of the standard treatment algorithms for patients with persistently elevated HbA1c despite multiple therapies.

Summary

The CATALYST clinical trial has demonstrated that mifepristone (Korlym) significantly improved glycemic control in patients with inadequately controlled type 2 diabetes who were found to have endogenous hypercortisolism. The randomized, double-blind, placebo-controlled study involving 136 participants showed a substantial 1.32% placebo-adjusted reduction in HbA1c after 24 weeks of treatment. The trial builds on findings that identified hypercortisolism in nearly one-quarter of patients with inadequately controlled type 2 diabetes using the 1-mg overnight dexamethasone suppression test. Mifepristone demonstrated a mean HbA1c reduction from 8.62% at baseline to 7.12% at week 24, compared with minimal change in the placebo group. These glycemic improvements were accompanied by reductions in glucose-lowering medications, particularly insulin, as well as significant weight loss and improvements in other metabolic parameters. However, treatment was associated with notable adverse events, including hypokalemia in 29.7% of patients, fatigue, nausea, and increases in blood pressure, resulting in higher discontinuation rates compared to placebo. The findings suggest that screening for hypercortisolism should be considered in patients with type 2 diabetes who appear resistant to conventional therapies, potentially identifying a subpopulation who might benefit more from cortisol-directed therapy than from additional glucose-lowering medications. The results open new possibilities in the diabetes treatment landscape and represent an important step toward more personalized approaches to diabetes management.